MARKET

TLSA

TLSA

TIZIANA LIFE SCIENCES PLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.23
+0.22
+3.14%
Closed 16:00 09/13 EDT
OPEN
7.07
PREV CLOSE
7.01
HIGH
7.76
LOW
7.05
VOLUME
9.19K
TURNOVER
--
52 WEEK HIGH
12.17
52 WEEK LOW
5.00
MARKET CAP
100.54M
P/E (TTM)
-12.0140
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TLSA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TLSA News

  • Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers
  • Business Wire.5d ago
  • Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma
  • Business Wire.09/04 12:00
  • Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
  • Business Wire.07/22 06:10
  • Tiziana Life Science reports Independent Third Party Article in New England Journal of Medicine on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes
  • Business Wire.07/01 08:24

More

Industry

Investment Trusts
+19.85%
Collective Investments
+0.83%

Hot Stocks

Name
Price
%Change

About TLSA

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.
More

Webull offers Tiziana Life Sciences PLC (TLSA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.